Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study
Related Experiment Video
Updated: Dec 11, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
Alain H Litwin1,2,3, Laura Shafner4, Brianna Norton5
1Department of Medicine, University of South Carolina School of Medicine-Greenville, Greenville, South Carolina, USA.
Abstract:
This study evaluated health outcomes among people who inject drugs who are infected with hepatitis C virus using an artificial intelligence platform. Mean (SD) cumulative adherence (visual confirmation of administration) was 91.3% (10.5%). Most subjects (88.2%) achieved ≥80% adherence to treatment, and 88.2% (15 of 17) achieved a sustained virologic response.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Subviral Agents
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Accumulation During Multiple Dosing: Repetitive IV Injections

